Bharat Parenterals Ltd — Dividend/Bonus, 18-05-2026: Corp. Action

Bharat Parenterals' board met, approving the audited financial results for the quarter and year ended March 31, 2026. Consolidated revenue reached ₹345.4 Cr, a slight increase from ₹340.0 Cr last year. EBITDA surged to ₹15.8 Cr from ₹2.7 Cr, significantly narrowing the net loss to ₹27.3 Cr from ₹43.7 Cr. The board proposed a final dividend of ₹1.00 per equity share (10%) for the financial year. Additionally, M/s. Chetan Gandhi & Associates were re-appointed as Cost Auditor and M/s. Dhruvik Parikh & Co. as Internal Auditor for FY2026-27, ensuring continued financial oversight.